Daly James M reported grant involving 9,311 derivative units of ACADIA PHARMACEUTICALS INC at $0.00 for $0 on May 29, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Jun 1, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
9,311Restricted Stock Units
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
9,311Direct
Trade date
May 29, 2026Grant
Filed
Jun 1, 2026, 6:00 PM ET3-day reporting delay
Accession
0001560782-26-000002Code A · Transaction 388195
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 29, 2026Option exercise8,107$0.00$0Trade 388193
May 29, 2026Grant16,004$0.00$0Trade 388194
May 29, 2026Option exercise8,107——Trade 388192
4 transaction rows in this filing. Joint filers share the same rows.

ACAD price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ACAD · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +3.2%1w ago −2%1d ago +0.5%
Returns since7d +0.8%30d +17%90d +35%180d1y

Footnotes in full

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.